Cytoreductive nephrectomy in the current treatment algorithm
| Autor: | Bernadett Szabados, Axel Bex, Teele Kuusk, Thomas Powles, Wing K. Liu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
renal cell carcinoma
medicine.medical_treatment sunitinib 030232 urology & nephrology Review Systemic therapy metastatic renal cell carcinoma lcsh:RC254-282 Targeted therapy law.invention systemic therapy 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Renal cell carcinoma law tyrosine kinase inhibitors medicine Cytoreductive nephrectomy Sunitinib business.industry Immunotherapy medicine.disease targeted therapy lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Oncology 030220 oncology & carcinogenesis Challenging Dogma: New Evidence to Guide Practice in Urologic Oncology immunotherapy business Algorithm medicine.drug cytoreductive nephrectomy |
| Zdroj: | Therapeutic Advances in Medical Oncology, Vol 11 (2019) Therapeutic Advances in Medical Oncology |
| ISSN: | 1758-8359 |
| Popis: | The two recent prospective randomized trials CARMENA and SURTIME have changed the therapy paradigm of metastatic renal cell carcinoma. The CARMENA trial was conducted to investigate whether cytoreductive nephrectomy (CN) is required in the targeted therapy area, whereas SURTIME studied whether deferred CN in combination with sunitinib can be used to identify patients with inherent targeted therapy resistance. In the current review, we provide a comprehensive discussion of two randomized studies and the current evidence with up-do-date algorithms for treating primary metastatic clear-cell renal cell carcinoma in the era of targeted therapy and immune-checkpoint inhibition. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|